Latest news with #ShivaniNyati
Mint
7 hours ago
- Business
- Mint
Brigade Hotel Ventures share price gains after weak listing. Should you buy, sell or hold the stock?
Brigade Hotel Ventures share price gained over 7% after making a weak stock market debut on Thursday. Brigade Hotel Ventures IPO listing date was today, 31 July 2025, and the equity shares were listed on BSE and NSE at a discount to the issue price. Brigade Hotel Ventures shares were listed at ₹ 81.10 apiece on NSE, a discount of 9.89% to its issue price of ₹ 90 per share. On BSE, the stock began trading at ₹ 82, down 8.89% from the issue price. However, buying emerged at lower levels and Brigade Hotel Ventures share price rallied as much as 7.07% from its listing price to an intraday high of ₹ 87.80 apiece on the BSE. Despite the gains, the stock is still nearly 4% below its issue price. Brigade Hotel Ventures IPO listing was below Street estimates, as the Brigade Hotel Ventures IPO GMP today, or grey market premium today, ahead of the share debut was muted. Brigade Hotel Ventures IPO investors who received allotment are suffering losses on their investors as the stock trades below IPO price. Here's what should investors do with Brigade Hotel Ventures shares: Shivani Nyati, Head of Wealth at Swastika Investmart Ltd., noted that the Brigade Hotel Ventures IPO enjoyed robust investor interest in the retail and institutional categories, though sentiment cooled significantly before listing, resulting in a below‑par debut. 'The lack of a listing premium despite initial GMP optimism reflects mixed confidence in short‑term growth and sector headwinds. However, the company's strategic parentage, asset footprint, occupancy strengths, and hotel partnerships could support medium‑ to long‑term value appreciation,' said Nyati. She recommends high risk investors to hold Brigade Hotel Ventures shares for medium to long term. Yash Chauhan, Research Analyst, INVasset PMS said that while Brigade Hotel Ventures share debut lacked momentum, the long-term story remains backed by marquee assets, strategic locations, and brand tie-ups. 'Near-term focus, however, must remain on operational leverage and margin improvement,' said Chauhan. At 2:35 PM, Brigade Hotel Ventures share price was trading at ₹ 86.38 apiece, higher by 5.34% than its listing price, and lower by 4.02% than its issue price on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
21-07-2025
- Business
- Economic Times
Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?
Live Events About Anthem Biosciences Anthem Biosciences' financial performance (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The shares of the newly listed Anthem Biosciences rallied 3.3% on the BSE to their intraday high of Rs 746.70 in Monday's trade, after listing at a healthy premium of 27% over its IPO the IPO investors are already sitting on an overall gain of 31%.Anthem Biosciences made a strong debut on the stock market with a listing gain of approximately 26.84% over its issue price of Rs 570, getting listed at around Rs 723. The IPO garnered massive investor interest, achieving an impressive overall subscription of 67.42 times, reflecting high demand across all issue had no fresh component, and the proceeds will go entirely to selling shareholders. Anchor investors had already pumped in Rs 1,016 crore before the IPO a bumper listing on the bourses, should you buy the shares of Anthem Biosciences?Shivani Nyati, Head of Wealth at Swastika Investmart , advises investors to secure partial profits and retain the remainder with a stop-loss set at Rs 650.'The company is one of the leading global players in the innovation-driven, technology-focused CRDMO segment . It enjoys a niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods,' noted Prashanth Tapse, Senior VP (Research) at Mehta Equities, highlighted, 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility,' while recommending a 'hold' rating on the stock.'Looking at its all financial as well as sectorial, we recommend investors to 'HOLD' the Anthem Biosciences for a long-term perspective. For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing,' he the short term, he foresees Rs 900 as the target, while the long-term investors can hold it for Rs 1,000 and the non-allottees, it is advised to wait for some volatility to settle in price and in case, if the stock is available around Rs 650-680, it can be considered as a good range to accumulate with long-term in 2006, Anthem operates across the drug development lifecycle—discovery, development, and commercial manufacturing—for both small molecules and 196 projects underway, a global customer base across 44 countries, and a growing portfolio of fermentation-based APIs and specialty ingredients, the company has carved a niche in India's pharma value FY25, Anthem reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore. EBITDA came in at Rs 684 crore with a strong margin of nearly 37%, while debt levels remained low.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
21-07-2025
- Business
- Time of India
Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?
Live Events About Anthem Biosciences Anthem Biosciences' financial performance (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The shares of the newly listed Anthem Biosciences rallied 3.3% on the BSE to their intraday high of Rs 746.70 in Monday's trade, after listing at a healthy premium of 27% over its IPO the IPO investors are already sitting on an overall gain of 31%.Anthem Biosciences made a strong debut on the stock market with a listing gain of approximately 26.84% over its issue price of Rs 570, getting listed at around Rs 723. The IPO garnered massive investor interest, achieving an impressive overall subscription of 67.42 times, reflecting high demand across all issue had no fresh component, and the proceeds will go entirely to selling shareholders. Anchor investors had already pumped in Rs 1,016 crore before the IPO a bumper listing on the bourses, should you buy the shares of Anthem Biosciences?Shivani Nyati, Head of Wealth at Swastika Investmart , advises investors to secure partial profits and retain the remainder with a stop-loss set at Rs 650.'The company is one of the leading global players in the innovation-driven, technology-focused CRDMO segment . It enjoys a niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods,' noted Prashanth Tapse, Senior VP (Research) at Mehta Equities, highlighted, 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility,' while recommending a 'hold' rating on the stock.'Looking at its all financial as well as sectorial, we recommend investors to 'HOLD' the Anthem Biosciences for a long-term perspective. For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing,' he the short term, he foresees Rs 900 as the target, while the long-term investors can hold it for Rs 1,000 and the non-allottees, it is advised to wait for some volatility to settle in price and in case, if the stock is available around Rs 650-680, it can be considered as a good range to accumulate with long-term in 2006, Anthem operates across the drug development lifecycle—discovery, development, and commercial manufacturing—for both small molecules and 196 projects underway, a global customer base across 44 countries, and a growing portfolio of fermentation-based APIs and specialty ingredients, the company has carved a niche in India's pharma value FY25, Anthem reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore. EBITDA came in at Rs 684 crore with a strong margin of nearly 37%, while debt levels remained low.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
&w=3840&q=100)
Business Standard
17-07-2025
- Business
- Business Standard
Smartworks Coworking Spaces shares list at 7% premium; book profit or hold?
Smart works Coworking Spaces share price: Shares of Smart works Coworking Spaces made a positive D-Street debut on Thursday, July 17, following the completion of its initial public offering (IPO). The company's shares listed at ₹436.10 per share on the BSE, a premium of ₹29.10 per share or 7.15 per cent over the issue price of ₹407 per share. On the National Stock Exchange (NSE), Smartworks Coworking Spaces shares listed at a slightly lower premium of ₹28 or 6.88 per cent at ₹435 apiece. Smartworks Coworking Spaces IPO listing was almost in line with the grey market's estimates. Ahead of their market debut, the unlisted shares of Smartworks Coworking Spaces were trading at ₹432 per share, reflecting a grey market premium of ₹25, or 6.14 per cent over the issue price, revealed sources tracking unofficial market activity. Should you book profit or hold? Shivani Nyati, head of wealth, Swastika Investmart, remains optimistic about the company's long-term outlook. "The company has posted growth in its top line with cash earnings before interest, taxes, depreciation, and amortisation (Ebitda) at gross levels," said Nyati, adding, "Its focus on MNC customers with long-term contracts has yielded the desired benefits." "Knowledgeable investors might park modest sums of money for the medium to long term, while others might consider taking profits," she added. Smartworks Coworking Spaces IPO details The public offering of Smartworks Coworking Spaces comprised a fresh issue of 10.9 million equity shares, aggregating to ₹445 crore, and an offer for sale (OFS) of up to 3.4 million equity shares worth ₹137.56 crore. It was offered at a price band of ₹387 and ₹407 per share, with a minimum lot size of 36 shares from July 10–July 14. Smartworks Coworking Spaces IPO received a positive response from investors and ended up getting oversubscribed by 13.45 times, riding on the back of the Qualified Institutional Buyers (QIBs), who oversubscribed the category reserved for them by 24.41 times. This was followed by the Non-Institutional Investors (NIIs) at 22.78 times, and Retail Investors at 3.53 times. Smartworks Coworking Spaces will not receive any proceeds from the offer for sale. The funds raised through the OFS will go directly to the selling shareholders. The company, however, proposes to use the net proceeds from the fresh issue to repay or prepay certain borrowings, invest in capital expenditure for fit-outs in new centres, and cover security deposits for these new centres. A portion of the funds will also be directed towards general corporate purposes. About Smartworks Coworking Spaces Smartworks Coworking Spaces Ltd (SCSL), incorporated in 2015, is India's largest managed campus operator offering 8.99 mn sq. ft. of leased and managed space across 50 centers in 15 cities (as of March 2025). Catering to mid-to-large enterprises, SCSL converts bare-shell properties into fully serviced, tech-enabled campuses featuring amenities like cafeterias, gyms, crèches, medical centers, and convenience stores to boost productivity and employee well-being. As of June 2025, it had a total capacity of 231,548 seats across 48 operational centers (190,421 seats), 2 under fit-out (15,042 seats), and 4 upcoming (26,085 seats).
Mint
17-07-2025
- Business
- Mint
Smartworks Coworking Spaces share price soars 8% after decent listing. Should you buy, sell or hold?
Smartworks Coworking Spaces IPO listing in focus: Smartworks Coworking Spaces made a healthy debut on Dalal Street today, July 17, as the stock listed with a 7% premium at ₹ 435 apiece on the NSE, compared to the issue price of ₹ 407. On the BSE, it opened 7.15% higher at ₹ 436. Following the decent listing, the stock maintained its momentum, gaining another 8% to hit the day's high of ₹ 469 apiece, about 15.23% above the IPO price. Although the shares debuted with modest gains, analysts remain optimistic about the company's long-term prospects. Shivani Nyati, Head of Wealth at Swastika Investmart Ltd., said the company had a quiet, in-line-to-positive debut on the stock market with a listing gain of approximately 7%, listing around ₹ 435. 'The company has posted growth in its top line, with cash EBITDA at gross levels. Its focus on MNC customers with long-term contracts has yielded the desired benefits. Knowledgeable investors might consider parking modest sums for the medium to long term, while others may book profits,' she added. The issue was open for bidding from July 10 to July 14 and received a healthy response from investors, closing with a subscription of 13.92 times. The IPO comprised a fresh issue of 1.09 crore shares aggregating to ₹ 445 crore and an offer for sale of 0.34 crore shares worth ₹ 137.56 crore. The offering attracted bids for 14 crore shares against the 1 crore shares on offer. The retail investor category was subscribed 3.69 times, while the non-institutional investor (NII) segment saw a subscription of 23.68 times. The qualified institutional buyer (QIB) portion was subscribed 24.92 times. The company plans to utilize the net proceeds from the issue for repayment or prepayment of certain borrowings, capital expenditure for fit-outs in new centers, security deposits for new centers, and general corporate purposes. Smartworks Coworking is described as an office experience and managed campus platform. As per the RHP report, it is the largest managed campus operator among its benchmarked peers in terms of total stock as of March 31, 2024, with a leased and managed super built-up area (SBA) of 8.00 million square feet. In terms of operational footprint, Smartworks manages 41 centers across 13 cities as of March 31, 2024. These include key business hubs such as Bengaluru, Pune, Hyderabad, Gurugram, Mumbai, Noida, and Chennai. The total seat capacity stood at 182,228 across the managed SBA of 8.00 million square feet. The company's revenue from operations comprises income from lease rentals, ancillary services, and software fees. For FY25, the company reported revenue of ₹ 1,409.67 crore, compared to ₹ 1,113 crore in FY24 and ₹ 744 crore in FY23. However, the company has reported net losses over the past three fiscal years, with a net loss of ₹ 63.18 crore in FY25, compared to ₹ 49.96 crore in FY24 and ₹ 101 crore in FY23. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
